News and Events

Recent Releases

05/23/2016 - 2:00pm

Study available at U-M evaluates reparixin in combination with paclitaxel for metastatic triple-negative breast cancer

ANN ARBOR, Mich. – An international clinical trial is testing an investigational study drug designed to target cancer stem cells in women with triple-negative breast cancer.

Triple-negative is the most aggressive kind of breast cancer. Triple negative tumors are negative for estrogen receptor, progesterone receptor and the HER2 protein. Because treatments that target these proteins would not work in triple negative breast cancer, the main treatment for it is chemotherapy.

05/18/2016 - 10:15am

Honors and awards for U-M Cancer Center faculty

U-M Comprehensive Cancer Center faculty receive many awards and honors. Here are some recent accomplishments.

05/18/2016 - 9:45am

The spring 2016 issue of THRIVE is online!

This issue features three patient stories about clinical trials: two immunotherapy and one precision medicine. It also covers Vice President Joe Biden's cancer moonshot and information about symptom management and alternative/complementary therapy.
05/17/2016 - 11:00am

30% of female physicians report sexual harassment

In a survey of high-achieving physician-scientists, nearly a third of women reported experiencing sexual harassment.

05/11/2016 - 11:30am

Quality of life meets cure for prostate cancer treatment

A new paper looks at how MRI and a clear understanding of the functional anatomy around the prostate can allow radiation oncologists to plan a course of treatment for patients with prostate cancer that spares these critical structures.

All Releases